Association between inflammatory obesity phenotypes, FTO-rs9939609, and cardiovascular risk factors in patients with type 2 diabetes

Meysam Alipour, Hosein Rostami, Karim Parastouei

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Background: The role of inflammatory states in cardiometabolic risks among patients with type 2 diabetes mellitus (T2DM) with similar degrees of obesity is unknown. The study aimed to compare cardiometabolic risk factors in inflammatory obesity phenotypes with regard to the role of the *FTO* rs9939609 gene polymorphism. **Materials and Methods:** This study was performed on 155 patients with T2DM (77 men and 78 women) in Ahvaz, Iran. Participants were grouped into four groups based on the presence of obesity and inflammation (high-sensitivity C-reactive protein ≥3.9 mg/L): low inflammatory normal weight (LINW), high inflammatory normal weight (HINW), low inflammatory obese (LIO), and high inflammatory obese (HIO). The genotypes of *FTO* rs9939609, including homozygous carriers of the *FTO* risk allele (AA), heterozygous carriers (AT), and carrying no risk allele (TT), were studied. The cardiometabolic risk factors, including anthropometric status, hypertension, lipid and glycemic profile, and inflammatory markers, were evaluated. The waist–hip ratio (WHR), mean arterial pressure (MAP), and atherogenic index of plasma (AIP) were calculated. **Results:** The patients in inflammatory groups (HINW and HIO) have significantly higher levels in AIP when compared to inflammatory healthy groups (LINW and LIO). No significant differences between any of the four group means were detected in WHR, blood pressure, MAP, glycemic status (fasting blood sugar and insulin), homeostatic model assessment, lipid profile (triglyceride, very low-density lipoprotein, high-density lipoprotein, low-density lipoprotein, and cholesterol), interleukin-6, and total antioxidant capacity. The most frequent of high-risk genotype (AA) of *FTO* rs9939609 was in HIO, LIO, HINW, and LINW. **Conclusion:** T2DM patients with inflammatory condition have similar degree of increased atherogenic risk irrespective of obesity. The obesity-risk genotype AA of *FTO* gene was associated with an increased risk for inflammatory obesity in T2DM patients.

Key words: C-reactive protein, diabetes mellitus, FTO, inflammation, obesity

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is ninth major cause of death and accounts for approximately 451 million (age 18–99 years) cases in worldwide.[1,2] Obesity, sedentary lifestyle, dyslipidemia, unhealthy dietary pattern, and nutrients deficiency are important risk factors for the T2DM development and its complications.[3,4] The cardiometabolic risk factors, including hypertension, insulin resistance, dyslipidemia, and cardiovascular disease (CVD), are greater in patients with T2DM compared to healthy people. However, T2DM-related complications are not same for all patients with T2DM.[5] Previous studies showed that the vascular atherosclerotic risks were higher in abdominally obese diabetic patients than in the diabetics without abdominal obesity.[6] It is recognized that obesity-related inflammatory cytokines (adipocytokines) are risk factors for the development of T2DM and its complications.[7] Excess adipose tissue in obese patients by activation of the immune system leads to an increase in interferon-γ-producing Th1 cells and a decrease in anti-inflammatory regulatory T cells, which induces insulin resistance.[8] However, various forms of obesity do not have the same adverse effects on health status. Not all obese people display inflammatory

Address for correspondence: Dr. Karim Parastouei, Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. E-mail: parastouei@gmail.com

unhealthy state and not all normal-weight people have inflammatory healthy state.[9] In addition, studies have shown that C-reactive protein (CRP) is an inflammatory marker independent of obesity associated with glycemic status.[10]

Therefore, it is possible that inflammatory or noninflammatory obesity could be helpful in explaining the variation in the cardiometabolic risk factors in T2DM. It seems that noninflammatory obesity phenotype is a low-risk subgroup and inflammatory nonobesity phenotype is a high-risk subgroup for CVD. Therefore, the assessment of cardiometabolic risk factors in inflammatory subgroup among obese people needs more research.[11]

Finding out the etiology of inflammatory obesity in T2DM is important. *FTO* (fat mass and obesity associated) gene is one of genetic factors for predisposing to T2DM, obesity, and probably inflammatory obesity.[12] The previous studies have shown that the *FTO*-rs9939609 risk variant (A allele) was associated with increased risk of T2DM and indices of obesity such as body mass index (BMI), hip circumference (HC), waist circumference (WC), and waist–hip ratio (WHR) compared to wild type (TT).[13,14] In addition, evidence suggests that there is a significant relationship between *FTO* rs9939609 polymorphism A allele and more high-sensitivity CRP (hs-CRP) levels.[15]

Currently, there is no consistent evidence regarding differences in terms of cardiovascular risk factors between inflammatory and noninflammatory obese diabetic patients. In addition, no study has been evaluated the role of *FTO* rs9939609 polymorphism in inflammatory obese patients. Thus, the aim of our study was to compare cardiometabolic risk factors in inflammatory obesity phenotypes with regard to the role of the *FTO* rs9939609 gene polymorphism.

MATERIALS AND METHODS

Participants

A cross-sectional study was performed in Ahvaz, Southwest of Iran, during 2018–2019. In the present study, 165 patients with T2DM using simple random sampling were screened from an endocrine clinic. Patients with T2DM were screened based on fasting blood sugar (FBS) >126 mg/dl and recruited based on the inclusion and exclusion criteria. Inclusion criteria were as follows: 20–65 years of age and BMI between 18.5 and 35 kg/m². Exclusion criteria were as follows: pregnancy, lactation and estrogen therapy in women, insulin therapy, inflammatory disease and use of anti-inflammatory agents, liver dysfunction, adrenal or thyroid dysfunction, and cancer. Obesity was defined based on BMI >30 kg/m². The inflammation condition was defined as a serum hs-CRP level >3.9 mg/L based on the optimal

cutoff point of hs-CRP for inflammatory state in diabetic patients. Participants were grouped into four groups: (1) low inflammatory normal weight (LINW), (2) high inflammatory normal weight (HINW), (3) low inflammatory obese (LIO), and (4) high inflammatory obese (HIO).

Ethical approval

The study protocol conforms to the ethical guidelines of the Declaration of Helsinki, and all procedures involving patients were approved by the Ethics Committee of Baqiyatallah University of Medical Sciences, Tehran, Iran. Furthermore, informed consent form was obtained from the participants.

Anthropometric and blood pressure measurement

Weight and height of individuals were determined in an overnight fasting status using a standard scale (Seca). BMI was calculated using the formula: (weight [kg])/(height² [m]). WC and HC were measured. WHR was calculated. The systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were measured. To evaluate the patient's blood pressure, the participants sit on a chair and have no physical activity 1 h. The mean arterial pressure (MAP) was calculated: ([2DBP + SBP]/3).[16]

Dietary intake and physical activity measurement

The usual dietary intake of participants in the previous year was collected by the interviewer using the valid and reliable food frequency questionnaire. Physical activity level was questioned. Physical activity defined as: ≥3 times/week and each time >30 min.

Biochemical measurements

The blood samples were collected in the fasting status. The blood samples were centrifuged. Part of the serum was used to evaluate the lipid profiles. The concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) were measured by an autoanalyzer. The atherogenic index of plasma (AIP) was calculated as the logarithm of molar ratio of TG/HDL-C.[17] FBS was immediately measured using enzymatic method by Pars–Azmoon kits (Tehran, Iran). The serum hs-CRP, insulin, interleukin-6 (IL-6), and total antioxidant capacity (TAC) concentrations were assessed by ELISA kits. The insulin resistance in the homeostasis model (homeostatic model assessment-insulin resistance [HOMA-IR]) was calculated as follows: FBS (mg/dL) × fasting serum insulin (mU/mL)/405.

Genotyping of the *FTO* rs9939609

The genomic DNA extraction from whole blood was done by the DNA purification Kit according to the instructions of the manufacturer (Sinaclon, Iran). We used PCR-RFLP

(polymerase chain reaction-restriction fragment length polymorphism) of *FTO* rs9939609 gene for genotyping the single-nucleotide polymorphisms (SNPs).

The primers F: 5′-AACTGGCTCTTGAATGAAATAGGA TTCAGA-3′) and (R: 5′-AGAGTAACAGAGACTAT CCAAGTGCAGTAC-3′) were used for amplifying a DNA fragment (containing rs9939609 polymorphism).

The PCR product of the *FTO* rs9939609 was digested by restriction enzyme (*ScaI*), which recognized the SNP T to A in the first intron of FTO gene. The RFLP products were resolved by performing electrophoresis on a 2.5% agarose gel. The T allele produced a 182 bp band and the A allele produced 154 bp and 28 bp bands. Hence, homozygous wild-type TT genotype has the 182 bp band only; homozygous mutated AA genotype has the 154 and 28 bp bands; and heterozygous TA genotype has the 182, 154, and 28 bp bands.

Statistical analysis

The software SPSS 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze data. The data normality was checked by Kolmogorov–Smirnov test. The Chi-squared test, Student's *t*-test, and ANOVA were used to evaluate differences within groups, followed by the Tukey's *post hoc* test. $P < 0.05$ was considered statistically significant. Odds ratios for AIP-based obesity and *FTO* phenotypes were measured using logistic regression using low-risk groups as the reference.

RESULTS

Out of the 165 patients with T2DM recruited, ten had incomplete data (genotyping, blood results, dietary, and medical information). Consequently, the data were analyzed for 155 patients consisting of 77 (49.7%) males and 78 (50.3%) females, with a mean age of 53.03 ± 9.98 years (range: 20–65 years). Table 1 displays anthropometric and biochemical characteristics between males and females. The optimal cutoff point for hs-CRP to detect obese T2DM was 3.9 mg/L. The inflammation health was defined as a serum hs-CRP level <3.9 mg/L (sensitivity of 52% and specificity of 78.0%). Based on obesity and inflammatory state, the patients were grouped into four groups: 47 LINW (30.3%), 44 HINW (28.4%), 29 LIO (18.7%), and 35 HIO (22.6%).

Table 2 shows that there were no significant differences in dietary intake and demographic characteristics (age, gender, physical activity, dietary intake, education levels, and taking medication) between groups.

Table 3 indicates comparison of anthropometric measures and biochemical variables between four groups according

Table 1: General characteristics of the participants

Variables	Total (*n*=155)	Male (*n*=77)	Female (*n*=78)	P
Age (years)	53.03±9.98	52.39±10.42	53.64±9.55	0.44
Weight (kg)	80.46±12.47	85.93±11.86	75.21±10.71	<0.001
BMI (kg/m²)	29.64±3.80	28.67±3.37	30.57±3.97	0.002
WC (cm)	101.08±7.48	99.23±6.02	102.70±8.26	0.006
WHR	0.97±0.05	0.98±0.04	0.96±0.05	0.07
SBP (mmHg)	13.42±2.23	13.78±1.97	13.06±2.41	0.04
DBP (mmHg)	8.52±1.36	8.86±1.34	8.19±1.31	0.002
HR (*n*)	84.66±11.98	82.83±12.40	86.44±11.36	0.07
MAP	10.15±1.55	10.50±1.49	9.81±1.55	0.006
TG (mg/dl)	190.11±104.89	199.10±120.20	181.23±87.08	0.29
HDL (mg/dl)	48.77±9.49	45.87±6.54	51.63±11.02	<0.001
LDL (mg/dl)	76.49±28.54	75.24±28.66	77.68±28.56	0.60
Cholesterol (mg/dl)	161.63±38.70	157.19±38.28	166.01±38.87	0.15
VLDL (mg/dl)	38.35±21.96	40.48±25.59	36.25±17.59	0.23
AIP	0.54±0.25	0.57±0.25	0.51±0.25	0.08
FBS (mg/l)	176.79±65.97	169.52±57.91	183.97±72.73	0.17
Insulin (ng/dl)	13.09±6.04	13.20±5.55	12.99±6.50	0.83
HOMA-IR	5.62±3.31	5.56±3.18	5.67±3.43	0.85
hs-CRP (mg/l)	3.88±0.84	3.81±0.63	3.95±0.99	0.32
IL-6 (ng/dl)	2.02±1.53	1.99±1.65	2.04±1.42	0.85
TAC	0.39±0.12	0.42±0.10	0.38±0.14	0.03

BMI=Body mass index; WC=Waist circumference; WHR=Waist-to-hip ratio; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HR=Heart rat; MAP=Mean arterial pressure; TG=Triglyceride; HDL=High-density lipoprotein; LDL=Low-density lipoprotein; VLDL=Very-LDL; AIP=Atherogenic index of plasma; FBS=Fasting blood sugar; HOMA-IR=Homeostatic model assessment of insulin resistance; hs-CRP=High-sensitivity C-reactive protein; IL-6: Interleukin-6; TAC: Total antioxidant capacity

to the inflammatory condition. Based on within-group analysis, there were no significant differences in age between groups.

As expected, the BMI and WC were more in obese groups (LIO and HIO) than normal-weight groups (LINW and HINW). The patients in the inflammatory unhealthy groups (HINW and HIO) have significantly higher levels in AIP [Figure 1] and hs-CRP when compared to the inflammatory healthy groups (LINW and LIO). There were no significant differences between any of the four group in WHR, SBP, DBP, MAP, HR, glycemic status (FBS, insulin, and HOMA-IR), profile lipid (TG, VLDL, HDL, LDL, and cholesterol), IL-6, and TAC.

The genotype frequencies for *FTO* rs9939609 were 28.4%, 54.8%, and 16.8% for AA, AT, and TT genotype, respectively. Pearson's Chi-square test showed that there was a significant different between groups in the frequency of *FTO* rs9939609 genotype (AA, AT, and TT, $P = 0.003$). The most frequent of high-risk genotype (AA) was in HIO, LIO, HINW, and LINW, respectively [Table 4].

The odds ratios of AIP according to inflammatory obesity and *FTO* phenotypes are summarized in Table 5. The inflammatory unhealthy groups (HIO and HINW) had

## Table 2: Dietary intake and demographic characteristics according to the inflammatory condition

Variables	LINW (*n*=47)	HINW (*n*=44)	LIO (*n*=29)	HIO (*n*=35)	*P*
Age	53.57±9.58	53.01±12.11	51.38±8.08	53.71±9.24	0.78
Female/male	26/21	19/25	12/17	21/14	0.31
Physical activity, *n* (%)					
Inactive	44 (94)	42 (95)	28 (97)	34 (97)	0.60
Active	3 (6)	2 (5)	1 (3)	1 (3)	
Education levels, *n* (%)					
Diploma or less	45 (96)	40 (91)	24 (83)	32 (91)	0.30
University	2 (4)	4 (9)	5 (17)	3 (9)	
Medication, *n* (%)					
Anti-glycemic	42 (89)	40 (90)	27 (93)	30 (86)	0.79
Lipid-lowering	17 (36)	23 (52)	11 (38)	21 (60)	0.11
Dietary intake					
Energy (Kcal)	2155.45±83.92	2172.24±72.01	2186.23±60.31	2206.36±110.39	0.09
Fat (gr)	99.52±12.66	96.71±15.64	99.14±13.36	101.48±12.31	0.53
Protein (gr)	58.16±10.95	58.68±9.71	60.14±7.89	59.27±10.97	0.87
Carbohydrates (gr)	268.35±31.41	279.01±31.32	275.47±27.65	275.52±20.78	0.40
Fiber (gr)	14.68±4.42	16.42±8.49	15.39±6.34	13.94±4.57	0.38
Cholesterol (mg)	344.54±117.49	340.13±101.79	351.87±123.27	391.25±109.33	0.79
SFA (gr)	39.01±9.61	39.27±8.70	41.03±9.72	42.35±9.92	0.95
MUFA	31.53±5.91	31.02±5.75	31.13±5.25	31.73±5.59	0.94
PUFA	14.43±5.57	15.29±6.15	13.73±4.43	14.53±6.82	0.63
Vitamin A (mgr)	284.81±199.46	261.55±152.20	307.08±183.45	265.08±138.69	0.71
Vitamin D (μg)	6.21±6.52	6.21±7.61	8.09±6.24	5.61±5.86	0.53
Vitamin E (mg)	14.71±10.20	13.09±7.25	12.54±6.89	13.71±11.50	0.08
Vitamin K (mg)	70.02±35.10	67.33±34.74	63.06±35.74	53.92±28.04	0.22
Vitamin C (mg)	83.57±35.50	78.87±29.29	78.85±35.84	76.41±34.99	0.83
Folate (μg)	299.48±120.93	307.26±110.51	300.40±133.02	275.61±121.73	0.73
Magnesium (mg)	213.72±61.17	223.82±100.65	208.90±59.89	196.03±70.65	0.54
Zinc (mg)	8.27±2.63	8.01±2.35	7.64±1.12	8.35±2.22	0.10
Beta-carotene (mg)	1702.28±1249.96	1594.51±905.59	1805.54±1098.0	1505.12±864.49	0.70
Lutein (μg)	709.16±430.35	714.21±534.93	703.31±472.39	562.56±354.02	0.47
Lycopene (μg)	5625.97±3444.84	5847.70±4616.46	6533.01±5254.18	6527.84±4975.68	0.77

[a]Significant difference between LINW compared to HINW; [b]Significant difference between LINW compared to LIO; [c]Significant difference between LINW compared to HIO; [d]Significant difference between HINW compared to LIO; [e]Significant difference between HINW compared to HIO; [f]Significant difference between LIO compared to HIO. LINW=Low-inflammatory normal-weight; HINW=High-inflammatory normal-weight; LIO=Low-inflammatory obese; HIO=High-inflammatory obese; SFA=Saturated fatty acids; MUFA=Monounsaturated fatty acid; PUFA=Polyunsaturated fatty acid

Figure 1: Comparison atherogenic index of plasma levels between groups

higher odds ratios than LINW as reference group. Patients with genotype AA (odds ratio = 1.34 [0.16–11.19]) and AA-AT (odds ratio = 1.22 [0.21–6.96]) have shown nonsignificantly higher AIP levels compared to TT individuals.

DISCUSSION

In this study, we found that irrespective of obesity, T2DM patients with inflammatory unhealthy condition have similar degree of increased atherogenic risk compared to patients with inflammatory healthy phenotypes. In fact, our findings suggest that the role of inflammatory status in developing atherogenic problems is stronger than obesity. To our knowledge, this is the first study that has evaluated the association between inflammatory obesity phenotypes with cardiometabolic risk factors in T2DM patients.

In accordance with our findings, Lin *et al.* reported that HINW men have higher carotid intima–media thickness as a risk factor for subclinical atherosclerosis compared to

Table 3: Anthropometric and biochemical characteristics according to the inflammatory condition

Variables	LINW (*n*=47)	HINW (*n*=44)	LIO (*n*=29)	HIO (*n*=35)	*P*
BMI (kg/m²)	26.82±1.84[b,c]	27.50±1.79[d,e]	33.80±3.59	32.37±2.53	<0.001
WC (cm)	97.40±6.31[b,c]	97.92±5.41[d,e]	107.20±6.71	105.61±6.62	<0.001
WHR	0.96±0.04	0.98±0.04	0.95±0.06	0.97±0.05	0.12
SBP (mmHg)	13.90±2.23	13.27±2.14	13.29±2.08	13.04±2.43	0.33
DBP (mmHg)	8.86±1.43	8.43±1.33	8.60±1.23	8.10±1.33	0.08
HR (*n*)	81.27±12.20	87.81±12.50	87.04±9.47	83.88±12.40	0.06
MAP	10.54±1.55	10.04±1.54	10.16±1.41	9.74±1.61	0.13
TG (mg/dl)	174.17±113.25	207.32±112.15	164.03±76.44	211.49±99.89	0.14
HDL (mg/dl)	49.36±9.06	47.84±10.58	50.01±9.08	48.11±9.19	0.74
LDL (mg/dl)	78.34±30.01	74.34±30.18	78.41±26.79	75.01±26.51	0.88
Cholestrol (mg/dl)	161.87±41.60	162.09±38.71	161.55±33.08	160.77±40.57	0.99
VLDL (mg/dl)	35.27±24.35	42.46±23.94	33.34±15.10	41.51±20.25	0.19
AIP	0.48±0.27[a,c]	0.59±0.26[d]	0.48±0.18[f]	0.60±0.24	0.04
FBS (mg/l)	189.49±55.94	176.89±60.45	173.48±78.39	162.37±73.15	0.32
Insulin (ng/dl)	13.62±5.66	11.52±5.46	14.53±5.58	13.09±7.32	0.19
HOMA-IR	6.42±3.47	4.72±2.07	5.90±2.58	5.36±4.49	0.10
hs-CRP (mg/l)	3.40±0.74[b,c]	4.45±0.47[d]	3.26±0.83[f]	4.37±0.49	<0.001
IL-6 (ng/dl)	1.78±1.29	2.05±2.05	1.97±1.03	2.36±1.44	0.44
TAC	0.40±0.11	0.37±0.13	0.41±0.10	0.40±0.14	0.70

[a]Significant difference between LINW compared to HINW; [b]Significant difference between LINW compared to LIO, [c]Significant difference between LINW compared to HIO; [d]Significant difference between HINW compared to LIO; [e]Significant difference between HINW compared to HIO; [f]Significant difference between LIO compared to HIO. LINW=Low-inflammatory normal-weight; HINW=High-inflammatory normal-weight; LIO=Low-inflammatory obese; HIO=High-inflammatory obese; BMI=Body mass index; WC=Waist circumference; WHR=Waist-hip ratio; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HR=Heart rate; MAP=Mean arterial pressure; TG=Triglyceride; HDL=High-density lipoprotein; LDL=Low-density lipoprotein; VLDL=Very-LDL; AIP=Atherogenic index of plasma; FBS=Fasting blood sugar; HOMA-IR=Homeostatic model assessment of insulin resistance; hs-CRP=High-sensitivity C-reactive protein; IL-6: Interleukin-6; TAC: Total antioxidant capacity

Table 4: Fat mass and obesity associated (rs9939609) genotypes frequency in groups

Genotype	Total (%)	LINW (%)	HINW (%)	LIO (%)	HIO (%)	*P**
AA	44 (28.4)	7 (14.9)	12 (27.3)	9 (31.0)	16 (45.7)	0.003
AT	85 (54.8)	36 (76.6)	23 (52.3)	11 (38.0)	15 (42.9)	
TT	26 (16.8)	4 (8.5)	9 (20.4)	9 (31.0)	4 (11.4)	

*Difference between TT, AT and AA between four groups. LINW=Low-inflammatory normal-weight; HINW=High-inflammatory normal-weight; LIO=Low-inflammatory obese; HIO=High-inflammatory obese

Table 5: Odds ratios for atherogenic index of plasma based inflammatory obesity and *FTO*-rs9939609 Phenotypes

Groups	Inflammatory obesity phenotypes			
	LINW	HINW	LIO	HIO
OR	Reference	6.97 (1.23-39.33)	4.19 (0.43-55.43)	16.44 (2.17-124.68)
P		0.02	0.19	0.007
Groups	*FTO*-rs9939609 phenotypes			
	TT	AT	AA	AA-AT
OR	Reference	0.87 (0.13-5.72)	1.34 (0.16-11.19)	1.22 (0.21-6.96)
P		0.89	0.78	0.81

LINW=Low-inflammatory normal-weight; HINW=High-inflammatory normal-weight; LIO=Low-inflammatory obese; HIO=High-inflammatory obese; OR=Odd ratio; *FTO*=Fat mass and obesity associated

their noninflammatory counterparts. Furthermore, they suggested that LIO men have lower coronary artery calcium scores compared to their inflammatory counterparts. However, their results were not repeated among women.[18] A number of studies reported that high hs-CRP level is strongly associated with the number of CVD risk factors and metabolic syndrome components.[19,20] The study results of Zeba *et al*. showed that adults with hs-CRP >1 mg/L were more probable to have the cardiometabolic risk factors compared to adults with hs-CRP <1 mg/L.[21] The relative risks of cardiovascular events according to the highest quartile of hs-CRP demonstrated two times compared to the lowest quintile in women.[22]

The possible mechanisms of CRP role in plaque deposition and atherosclerosis are complex. CRP may facilitate monocyte adhesion and macrophage infiltration in atherosclerotic lesions.[23,24] Furthermore, CRP inhibited endothelial nitric oxide synthase and impaired vasoreactivity.[25] Evidences reported CRP found in lipid microdomains of endothelial cells and plaques.[26]

We did not find any different in glycemic profile between inflammatory obesity phenotypes. Previous studies indicated that elevated serum hs-CRP level was associated with an increased degree of glycemic variables.[27,28] On the other hand, some theories suggested that inflammation during obesity is not all bad for T2DM.[29]

Our results demonstrate that in T2DM patients, variants in the *FTO* rs9939609 gene predispose to inflammatory obesity. Fisher *et al*. reported that variation in the *FTO* rs9939609 gene may contribute to enhance inflammatory state independently of obesity. Their results suggested

that each additional copy of the obesity-risk allele (AA) of FTO gene was associated with an increase in CRP level (1.14-fold in men and 1.12-fold in women).[30]

Saucedo *et al*. suggested that lower concentrations of adiponectin and higher concentrations of pro-inflammatory tumor necrosis factor-alpha were associated with the *FTO* rs9939609 risk allele A in women with gestational diabetes mellitus after adjusting for maternal pregestational body weight.[31] Furthermore, recently, a study observed that the carriers of risk allele A of *FTO* Polymorphism rs9939609 had increased CRP and insulin values.[32] However, some studies did not report an association between the *FTO* rs9939609 variant and inflammatory state.[28,29] Animal studies demonstrated that independent of body weight, *FTO* gene influences the metabolic outcomes by alteration of nuclear factor kappa B signaling in hypothalamus.[33]

CONCLUSION

T2DM patients with inflammatory condition are at high risk for atherogenic risks than patients with inflammatory healthy status. The results of our research show the more importance of inflammatory status in the development of atherosclerosis compared to obesity. The nonobese patients with inflammatory condition indicated atherogenic risks similar to patients with inflammatory obesity, therefore, they should be considered as a high risk group. The obesity-risk genotype AA of *FTO* gene was associated with an increased risk for inflammatory obesity in T2DM patients.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, *et al*. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-81.
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88-98.
3. Aljack HA, Abdalla MK, Idris OF, Ismail AM. Vitamin D deficiency increases risk of nephropathy and cardiovascular diseases in type 2 diabetes mellitus patients. J Res Med Sci 2019;24:47.
4. Rahimi N, Samavati Sharif MA, Goharian AR, Pour AH. The effects of aerobic exercises and 25(OH) D supplementation on GLP1 and DPP4 level in type II diabetic patients. Int J Prev Med 2017;8:56.
5. Cox AJ, Hsu FC, Freedman BI, Herrington DM, Criqui MH, Carr JJ, *et al*. Contributors to mortality in high-risk diabetic patients in the diabetes heart study. Diabetes Care 2014;37:2798-803.
6. Lukich A, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: Relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol 2014;13:141.
7. Jaganathan R, Ravindran R, Dhanasekaran S. Emerging Role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes 2018;42:446-560.
8. Deng T, Liu J, Deng Y, Minze LJ, Xiao X, Wright V, *et al*. Adipocyte adaptive immunity mediates diet-induced adipose inflammation and insulin resistance by decreasing adipose Treg cells. Nature communications. 2017;8:15725.
9. Alam I, Ng TP, Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective. Mediators Inflamm 2012;2012:456456.
10. Ebrahimi M, Heidari-Bakavoli AR, Shoeibi S, Mirhafez SR, Moohebati M, Esmaily H, *et al*. Association of Serum hs-CRP Levels With the Presence of Obesity, Diabetes Mellitus, and Other Cardiovascular Risk Factors. J Clin Lab Anal 2016;30:672-6.
11. Kim SH, Després JP, Koh KK. Obesity and cardiovascular disease: Friend or foe? Eur Heart J 2016;37:3560-8.
12. Kamura Y, Iwata M, Maeda S, Shinmura S, Koshimizu Y, Honoki H, *et al*. FTO gene polymorphism is associated with type 2 diabetes through its effect on increasing the maximum BMI in Japanese men. PLoS One 2016;11:e0165523.
13. Sabarneh A, Ereqat S, Cauchi S, AbuShamma O, Abdelhafez M, Ibrahim M, *et al*. Common FTO rs9939609 variant and risk of type 2 diabetes in palestine. BMC Med Genet 2018;19:156.
14. Tupikowska-Marzec M, Kolačkov K, Zdrojowy-Wełna A, Słoka NK, Szepietowski JC, Maj J. The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis. Biomed Res Int 2019;2019:7304345.
15. Sun Y, Sun J, Wang X, You W, Yang M. Variants in the fat mass and obesity associated (FTO) gene are associated with obesity and C-reactive protein levels in Chinese Han populations. Clin Invest Med 2010;33:E405-12.
16. Ashtary-Larky D, Lamuchi-Deli N, Milajerdi A, Salehi MB, Alipour M, Kooti W, *et al*. inflammatory and biochemical biomarkers in response to high intensity resistance training in trained and untrained men. Asian J Sports Med 2017;8:e13739.
17. Karabay E, Karsiyakali N, Duvar S, Tosun C, Aslan AR, Yucebas OE. Relationship between plasma atherogenic index and final pathology of Bosniak III-IV renal masses: A retrospective, single-center study. BMC Urol 2019;19:85.
18. Lin A, Lacy ME, Eaton C, Correa A, Wu WC. Inflammatory obesity phenotypes, gender effects, and subclinical atherosclerosis in African Americans: The Jackson heart study. Arterioscler Thromb Vasc Biol 2016;36:2431-8.
19. Razban MM, Eslami M, Bagherzadeh A. The relationship between serum levels of hs-CRP and coronary lesion severity. Clujul Med 2016;89:322-6.
20. Seyedian SM, Ahmadi F, Dabagh R, Davoodzadeh H. Relationship between high-sensitivity C-reactive protein serum levels and the severity of coronary artery stenosis in patients with coronary artery disease. ARYA Atheroscler 2016;12:231-7.
21. Zeba AN, Delisle HF, Rossier C, Renier G. Association of high-sensitivity C-reactive protein with cardiometabolic risk factors and micronutrient deficiencies in adults of Ouagadougou, Burkina Faso. Br J Nutr 2013;109:1266-75.
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of

C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.

23. Badimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, *et al*. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol 2018;9:430.

24. Kones R. Primary prevention of coronary heart disease: Integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011;5:325-80.

25. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: Clinical relevance. Clin Chem 2009;55:206-8.

26. McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, *et al*. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of c-reactive protein and its conformational changes. Front Immunol 2018;9:1351.

27. Uemura H, Katsuura-Kamano S, Yamaguchi M, Bahari T, Ishizu M, Fujioka M, *et al*. Relationships of serum high-sensitivity C-reactive protein and body size with insulin resistance in a Japanese cohort. PLoS One 2017;12:e0178672.

28. Shaheer AK, Tharayil JK, Krishna PW. A comparative study of high sensitivity C-reactive protein and metabolic variables in type 2 diabetes mellitus with and without nephropathy. J Clin Diagn Res 2017;11:BC01-BC04.

29. Ye J, McGuinness OP. Inflammation during obesity is not all bad: Evidence from animal and human studies. Am J Physiol Endocrinol Metab 2013;304:E466-77.

30. Fisher E, Schulze MB, Stefan N, Häring HU, Döring F, Joost HG, *et al*. Association of the FTO rs9939609 single nucleotide polymorphism with C-reactive protein levels. Obesity (Silver Spring) 2009;17:330-4.

31. Saucedo R, Valencia J, Gutierrez C, Basurto L, Hernandez M, Puello E, *et al*. Gene variants in the FTO gene are associated with adiponectin and TNF-alpha levels in gestational diabetes mellitus. Diabetol Metab Syndr 2017;9:32.

32. Tupikowska-Marzec M, Kolačkov K, Zdrojowy-Wełna A, Słoka NK, Szepietowski JC, Maj J. The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis. Biomed Res Int 2019;2019:7304345.

33. Zimmermann E, Skogstrand K, Hougaard DM, Astrup A, Hansen T, Pedersen O, *et al*. Influences of the common FTO rs9939609 variant on inflammatory markers throughout a broad range of body mass index. PLoS One 2011;6:e15958.